Genmab stock gains as petosemtamab and Q2 figures draw focus

Published on 09/19/2026 at 18:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genmab stock rose to DKK 2,244 on September 16, 2026, with volume and market value still anchoring the move. The latest half-year report from August 6, 2026 showed revenue and operating progress.

Fotorealistisches Biotech-Labor mit Forschern in weißen Kitteln bei Antikörperforschung — Genmab A/S entwickelt Antikörpertherapien in modernen Biotech-Laboren mit Forschern und Präzisionsgeräten, Aktie DK0010272202, Illustration mit AI erstellt.

Genmab stock (ISIN DK0010272202) closed at DKK 2,244 on September 16, 2026, after a recent note on Ad-hoc-News tied the move to the Phase 3 start of petosemtamab and second-quarter figures. The same source put the ADR target at USD 40.00 and said the stock sat about 16 percent below that level on September 16, 2026.

Half-year numbers set the base

Genmab's latest IR update on Genmab A/S on August 6, 2026 covered first-half 2026 results, while the company also posted second-quarter DARZALEX net sales on July 15, 2026. Those two dated milestones give the stock a fresh operating frame heading into the autumn reporting cycle.

Genmab's first-half 2026 release on August 6, 2026 is the most recent full interim update in the company's IR stream, and it followed the first-quarter 2026 results on May 7, 2026. The share's recent DKK 2,244 close gives that reporting backdrop a visible market anchor.

Valuation stays in view

For investors, the next question is whether the market is pricing in the company's late-stage pipeline and the current consensus view. The ad-hoc summary on September 18, 2026 said one analyst house kept a USD 40.00 ADR target, which it described as roughly 16 percent above the September 16 close.

The same summary also said a Simply Wall St model placed fair value at DKK 2,454, or about 9 percent above the recent Copenhagen close of DKK 2,244. That leaves the stock trading below both the ADR target and the model estimate, with the gap measured in exact numbers rather than broad optimism.

Price and market data

Genmab stock was quoted at DKK 2,244 on September 16, 2026. The article hit did not provide a timestamped intraday quote, so the date-only close is the clean reference point here.